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Executive Summary 
Hormonal birth control methods have become increasingly popular since 2000, as the 
technology becomes more convenient for users, moving from daily pills, to weekly patches, to 
yearly implants. Implanon is an example of a long-term birth control implant. The goal of this 
project is to create an accurate computational model of Implanon’s hormone diffusion over its 
standard prescription length: three years. Because Implanon is intended for long-term use, any 
potential improvements in the drug or release mechanism take several years to clinically test. It is 
time and cost inefficient to develop several new designs and test them all over this long time 
period. Instead, we can eliminate those designs that fail to reach specifications in our computer 
model  and  be  more  confident  in  the  clinical  success  of  those  that  function  properly  in  our 
computer model, thus reducing the number of clinical trials needed and the time and money 
spent.  We  created  a  two-dimensional  cross  section  model  of  the  Implanon  implant  and 
surrounding tissue under mass transfer conditions model using COMSOL Multiphysics software.  
We confirmed our model’s accuracy with comparisons to published Implanon hormone release 
rates at six weeks, one year, two years, and three years. Our model’s hormone release rate was 
found to stay within a factor of 10 of the published data at all critical time periods. This data is 
significant in that it has the potential to expedite the hormone modification process. There were 
several assumptions made in the model’s schematic design as well as material properties and 
boundary parameters. It is recommended that more in vivo experimentation and data gathering on 
Implanon  implant  placement  and  hormone  diffusivity  be  conducted  to  improve  this  model’s 
accuracy. 
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Introduction 
Hormonal birth control includes a broad range of contraceptive methods that are fairly 
simple to use, have very few side effects, and when used correctly are very effective.  These 
methods range from daily pills to monthly intrauterine devices to yearly implants.  Hormonal 
birth control affects a woman by thickening the mucus membrane on the uterine walls such that 
sperm are not able to enter as well as preventing fertilized eggs from implanting on the uterine 
walls.  In the case of a constant release of drug, ovulation is also suppressed in the patient. 
The Implanon implant is a small (0.04 m by 0.002 m) cylindrical device that is placed 
under the skin of the upper arm of a woman.  It is designed to release the hormone etonogestrel 
to lessen the risk of conception.  The core of the implant contains sixty-eight milligrams of 
etonogestrel, which is released over a period of three years.  While the device can be removed at 
any time it is recommended that it remain for the full three years.  The drug released from the 
implant has the same general effects on a woman’s body with regards to pregnancy prevention. 
During the first six weeks after implantation, the experimental release rate of etonogestrel 
from the implant into the surrounding tissue is between 60 and 70 micrograms per day.  At the 
one year mark, the release rate was measured to be between 35 and 45 micrograms per day, and 
between 30 and 40 micrograms per day at the end of two years.  At the end of three years, the 
etonogestrel release rate was experimentally determined to be between 25 and 30 micrograms 
per  day  (Implanon,  2009).    Even  at  these  low  release  rates  the  contraceptive  power  is  still 
effective enough to suppress ovulation. 
Our project’s goal was to model the etonogestrel release mechanism from Implanon over 
a three year period when implanted in human tissues (epidermis and dermis) to reduce the cost 
and  time  associated  with  testing  future  Implanon  modifications.    The  model  will  take  into 
account the thicknesses of the different tissues as well as their specific properties, both material 
and physical. 
  The  computational  model  was  a  two-dimensional  transient  diffusion  problem  that 
monitored the concentration of hormone remaining in the implant and surrounding tissues before 
being  removed  by  nearby  blood  vessels  in  dermis  tissue.    Our  model  differs  from  the 
manufacturer’s experimentation because the manufacturer only released limited data on their 
experiment, excluding material properties such as diffusivity and flux values. 
Since the material properties were not provided in literature, the material properties used 
were found from various hormones or drugs that were similar in size and structure.  The three 
molecules used for material properties in the COMSOL model were etonogestrel (the working 
hormone), testosterone, and scopolamine. While the material properties were not available for 
the tissues, the diffusivities of etonogestrel in the implant core and in the membrane were found 
in published literature (van Laarhoven et al, 2002).   4 
 
Considerations in the design of the model were that the Implanon implant is a perfect 
cylinder and is considered to be infinitely long with respect to the diameter, such that the effect 
of the ends  of the implant  was  negligible.  The model’s  domain was  designed to  include a 
representative cross section of the implant within the surrounding tissues. 
Design Objectives 
Our project had three design objectives: 
  Determine if the diffusivities of similar drugs through tissues and blood are adequate 
approximations of the diffusivity of etonogestrel through tissues and blood 
  Model the release of etonogestrel from the Implanon implant into the surrounding tissues 
and removal through blood vessels 
  Compare  the  flux  rates  from  the  model  to  the  experimental  data  provided  by  the 
specification sheet from the Implanon distributor 
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Problem Schematic 
COMSOL Multiphysics was used to create a model of etonogestrel release over a period 
of three years in the skin surface tissues on the upper anterior portion of an adult female arm.  
The implant is modeled as a cylinder surrounded on all sides by tissues, both epidermis and 
dermis. In the model, the implant is considered to be an infinitely long cylinder, such that the 
effects of the ends are not considered in the model.  The radius of the implant core is 0.94 mm 
and the radius  of the implant  core and the membrane, or the total  radius,  is  1.0 mm.  The 
geometry of the implant was taken from Implanon, 2009.  The epidermis is modeled to be 1.5 
mm thick and the dermis is modeled to be 3.0 mm thick.  This problem was formulated using a 
two-dimensional model that includes the Implanon implant, the dermis, the epidermis, and four 
blood vessels that are dispersed within the dermis.  The geometry and dimensions of the model 
are shown in Figure 1. 
Schematic of Implanon Implant in Tissue: 
 
 
D core = 1.84 x 10
-13 m
2/s 
D membrane = 9.2 x 10
-15 m
2/s 
Inward Flux blood vessel = -7.5 x 10
-10 x c mol/m
2s 
 
r red = 0.00094 m 
r blue = 0.001 m 
r green = 0.000125 m 
 
Figure 1: Schematic of Implanon implant in tissues as entered in COMSOL Multiphysics. 
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In our problem’s governing equation, there is no reason to take convection into account 
due to the lack of fluid flow in the body tissues.  There is no generation or degradation term 
because  etonogestrel  is  only  degraded  and  removed  in  a  noticeable  range  in  the  liver  (See 
Appendix A).  All of the outer boundaries are set to have an impermeable condition, so that none 
of the drug is leaving the tissues through any method other than removal through the uptake into 
the blood stream through the blood vessels.  The blood vessels have a boundary condition of 
inward flux, No, that is a function of the concentration of etonogestrel at the blood vessel/tissue 
interface at any given time. 
The initial concentration of drug is located only in the Implanon core, and nowhere else.  
The drug concentrations in all of the tissues and in the implant membrane are all equal to zero. 
The simulation was run over a three year period with a time step of one hour for the first 
six weeks then with a time step of ten hours from six weeks to the three year ending point.  The 
simulation was run so that the flux at the boundary of the implant membrane can be calculated at 
given time points, six weeks, one year, two years, and three years, to compare with the data 
provided by the Implanon specifications sheet.  The time step was smaller in the initial six week 
period because that was the time of greatest variation in hormone release from the Implanon, and 
was increased after the initial six weeks because there would be less variation in hormone release 
as time continued on. 
The diffusivity of etonogestrel through the Implanon core was found to be 1.84 x 10
-9 
cm
2/s (van Laarhoven et al, 2002).  This value is the diffusion coefficient of etonogestrel in 
ethylene vinylacetate (EVA) 9.  EVA 9  is the copolymer through which many birth control 
implants are made out of, including Implanon.  This value, however, was found experimentally 
for etonogestrel in an intrauterine device.  Since the hormone and the material are the same, the 
diffusivity can be assumed to be accurate. 
The diffusivity of etonogestrel through the Implanon membrane, we know, should be 
much smaller than the diffusivity through the core.  The purpose of the membrane, which is also 
made out of EVA, is to further slow down the release of etonogestrel from the core into the 
tissues.  According to, Implanon, 2009, the diffusivity of etonogestrel through the membrane is 
twenty  times  smaller  than  the  diffusivity  of  etonogestrel  through  the  core.    This  value  was 
calculated to be, 9.2 x 10
-11 cm
2/s. 
The diffusivity of etonogestrel in the epidermis was not simple to find.  Since the value 
was never calculated in literature, the next best option was to find the value of a similar molecule 
in the same tissue.  For this, the diffusivity of the hormone testosterone through tissue was used.  
The  value  was  found  to  be  1.0  x  10
-10  cm
2/s  (Ebert,  1992).  Comparing  etonogestrel  to 7 
 
testosterone,  they  have  similar  molecular  substituent  groups  attached  to  central  six-member 
carbon rings and the molar masses differ by 36.037 g/mol. 
The diffusivity of etonogestrel in the dermis was also not found, again, the value was 
never calculated in literature.  The solution to this was to use the value of scopolamine, a drug 
that is diffused through a patch into the skin to prevent motion sickness.  The diffusivity of 
scopolamine through the dermis was found to be 5.8 x 10
-7 cm
2/s (Datta et al, 2010).  This value 
is a good approximation because the difference in the molar masses between etonogestrel and 
scopolamine is 21.104 g/mol. 
To determine the amount of etonogestrel that was being removed from the tissue through 
the blood at a given time was calculated by determining the inward flux, No.  First to do this, a 
value for the diffusivity of etonogestrel through the blood had to be found.  Since this value was 
not available in literature, the next best option was to find the diffusivity of a different hormone 
through a material similar to blood.  The diffusivity of testosterone through PDMS was found to 
be 1.8 x 10
-5 cm
2/min (Pereira et al, 1987).  To find the value of No the diffusivity was multiplied 
by the concentration, c.  This means that the inward flux would vary over time, as the 
concentration at the blood vessel/tissue boundary would change over time. 
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Results and Discussion 
The Implanon device contains 68 mg, or if expressed in concentration, 1668.0851 
mol/m
3,
 of etonogestrel according to (citation).   Using COMSOL Multiphysics, we modeled the 
2D diffusion problem to observe how etonogestrel leaves the implant, and how long the implant 
could sustain an adequate dosage of hormone to prevent pregnancy.  Using our model, we 
computed the diffusive flux of etonogestrel over a period of 3 years at the center of the Implanon 
core. 
 
Figure 2: Etonogestrel Flux at Center of Implanon Core (0,0) over a Time Period of Three Years 
(94,608,000 s) 
  As Figure 2 shows, the flux of etonogestrel initially rises rapidly as because the initial 
concentration gradient of the drug between the core and tissue layers is very large.  However, 
after only 45 days the flux reaches its maximum and starts to decrease.  The peak occurring at 
the 45 day mark is  significant  because  according to  the manufacturer,  Implanon achieved  a 
maximum release rate after 42 days (6 weeks).  The flux decreases rapidly after achieving its 
maximum because the concentration gradient of the etonogestrel between the core and tissue 
starts to decrease as more and more drug enters the bloodstream.  The following surface plots, 
Figure 3a-e, shows how the drug diffuses out of the implant after 6 weeks, 1 year, 2 years, and 3 
years. 
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e  
Figure 3: Surface Plots of Etonogestrel Concentration.  (a) Initial surface plot of model (time = 0 
s).  (b) Surface plot of model after six weeks (3,628,800 s).  (c) Surface plot of model after one 
year (31,536,000 s).  (d) Surface plot of model after two years (63,072,000 s).  (e) Surface plot of 
model after three years (94,608,000 s). 
  The  etonogestrel  concentration  ranges  for  each  of  the  surface  plots  in  Figure  3  are 
tabulated in Appendix C. The hormone seems to diffuse out of the Implanon device towards the 
upper boundary of the epidermis, or the top layer of skin and accumulating.  However, the 
diffusivity  of  etonogestrel  is  higher  in  the  dermis,  or  the  bottom  layer  of  skin,  than  in  the 
epidermis. Therefore, the hormone should be diffusing more into and through the dermis towards 
the blood vessels.  Upon closer analysis, we see that etonogestrel is indeed diffusing towards the 
blood vessels, as shown in Figure 4.   10 
 
 
Figure 4: Etonogestrel Flux Pattern, Flow pattern after six weeks (3,628,800s).  
  Figure 4a shows the concentration flow pattern for the model at six weeks.  It shows that 
etonogestrel in the upper section of the core is initially released towards the upper boundary of 
the epidermis.  This explains why there are significant amounts of etonogestrel (see Appendix C 
for  exact  concentrations)  still  in  the  tissue  at  the  end  of  the  three  year  period  tested.    The 
hormone seems to settle in two different sections near the upper boundary of the epidermis.  The 
two sections are equivalent due to the symmetries of the model. The hormone deposits near the 
boundary because the upper boundary of the epidermis has an insulated boundary condition.  
Therefore  any  etonogestrel  released  from  the  top  of  the  implant  diffuses  towards  the  upper 
boundary and seems to settle there.   
Figure  4  combined  with  Appendix  C  shows  that  the  maximum  concentration  of 
etonogestrel decreases over time.  Since the maximum concentration of etonogestrel is located at 
the upper boundary in Figures 3c, d, e, the hormone is clearly moving away from the upper 
boundary as time progresses.  Also the etonogestrel flow pattern at the end of the three year 
period confirms that etonogestrel is diffusing towards the blood vessels. 
  Overall, the model behaved as predicted, with etonogestrel leaving rapidly during the 
early part of the three year period, then slowing down.  The core had a low concentration of 
hormone  (13.78  mol/m
3)  left  after  three  years,  which  is  only  0.826%  of  the  original 
concentration.  The low concentration remaining in the core after three years was desired since 
the goal was to deliver all of the hormone into the body over the three year time frame.   
The  one  unexpected  result  was  etonogestrel  accumulation  in  the  upper  tissue.  The 
hormone settled here due to the setup of the model. Therefore, placing the implant at a slightly 11 
 
different  depth  and/or  placing  the  implant  further  into  the  dermis  layer  could  limit  the 
accumulation.   
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Accuracy Check 
The release rates out of the Implanon device were calculated by performing a Boundary 
Integration around the membrane of the implant to calculate the diffusive flux at 6 weeks, 1 year, 
2 years, and 3 years.  The results from our model were confirmed by comparing the rates at 
specified times over the three years to published release rates by the manufacturer (Implanon, 
2009).  
Table 1: Accuracy check of Manufacturer Data as compared to COMSOL Simulation and 
Percent Error. 
Accuracy Check Release rates (x10
-7 mol/day) 
   Manufacturer Data  COMSOL Simulation  Percent Error (%) 
6 Weeks  2.16  5.69  163.425 
1 Year  1.39  0.892  35.827 
2 Years  1.23  0.312  74.634 
3 Years  0.925  0.137  85.189 
 
The percent errors are large for our accuracy check for two reasons.  First, the values that 
we are comparing are very small, and therefore, the error is quite large for values that are 
actually quite close together.  Second, we do not have actual experimental data for many of the 
parameters for our model, but instead were using approximate values based on similar molecules 
through similar materials.  If we had the correct experimental data, we would expect the percent 
error to decrease. 
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Sensitivity Analysis 
Because much of our model was based on molecules similar to etonogestrel, and not 
etonogestrel itself, it is important to conduct sensitivity analyses to determine the significance of 
these various parameters’ uncertainty. We performed the sensitivity analysis on the inward flux 
of blood vessels, diffusivity in the dermis, and epidermis, as well as on the number of blood 
vessels surrounding the implant.  We did not perform sensitivity analysis on the Implanon core 
and membrane diffusivities because we have published data from the manufacturer stating the 
diffusivity properties of these two regions.  Since these values are particular to the drug, we are 
not going to change them. In each case of sensitivity analysis, a comparison was made between 
the newly calculated drug release rate and the original parameter’s drug release rate at 6 weeks, 1 
year, 2 years, and 3 years.  In the figures below, the release rates of the drug were monitored 
over the course of the 3 years with variations on each of the parameters that were not fixed.  
These analyses will show how sensitive or nor the model is to each of the parameters with 
regards to the release rate of etonogestrel. 
a b       
c d  
Figure 5: Sensitivity Analysis of Etonogestrel Diffusivity. (a) Sensitivity analysis of etonogestrel 
in blood. (b) Sensitivity analysis of etonogestrel in dermis. (c) Sensitivity analysis of 
etonogestrel in epidermis. (d) Sensitivity analysis of number of blood vessels. 
The etonogestrel diffusivity in blood, in dermis, and epidermis all had a significant 
impact on the release rates of the hormone from the core.  The etonogestrel diffusivity in blood 
had the greatest impact on the 6 week release rate, while the other release rates were impacted 
only slightly.  The hormone diffusivity in the epidermis tissue layer had great impacts on all four 14 
 
of the release rates (6 weeks, 1 year, 2 years, and 3 years), while the hormone diffusivity in the 
dermis had small impacts on each of the release rates.  Surprisingly, the number of blood vessels 
did not have an impact on any of the release rates.  This is unexpected because the blood vessels 
are the only way that the etonogestrel is able to leave the tissues, and the logical assumption 
would be that the fewer the blood vessels the lower the release rate (while all other properties 
remain consistent).  However, if the number of blood vessels does not matter, then the 
uncertainty in our model on how the blood vessels actually interact with etonogestrel can be 
ignored.   15 
 
Conclusion 
The goal of designing an accurate model of etonogestrel diffusion from the implant and 
through the layers of tissue into the blood vessels was able to be achieved.  Based on diffusion 
values calculated and the sensitivity analysis conducted to determine the relative amounts of 
uncertainty in the parameters selected, the model does exhibit release rates similar to those given 
in the literature, and the trend of decreasing rate of release over time is followed.  
At the time of six weeks, the model gave a release rate of 6.56 x 10
-7 mol/day, while the 
manufacturer claimed that there was a release of 2.16 x 10
-7 mol/day. This difference in values 
between the data from COMSOL and the data from the manufacturer decreased for the period of 
one year (0.837 x 10
-7 mol/day for the model versus 1.39 x 10
-7 mol/day for the manufacturer), 
and then leveled off for two years (0.279 x 10
-7 mol/day for the model versus 1.23 x 10
-7 mol/day 
for the manufacturer),  and three years  (0.119 x 10
-7 mol/day for the model versus 0.925 x 10
-7 
mol/day for the manufacturer). The model data shows that, as detailed by the manufacturer, the 
release rate of etonogestrel from the Implanon device decreases as the concentration of the drug 
inside the implant decreases. Given the relative simplicity of the model in relation to the intricate 
nature  of  human  dermis  and  epidermis  and  the  many  assumptions  made  in  the  model,  the 
accuracy of the results simulated from COMSOL is fairly high.  
Although there was no readily available data for the diffusion of etonogestrel into the 
blood and testosterone is structurally a very similar molecule, improvements could be made to 
the model to prepare for future publications. This, as well as the other assumptions made in the 
model, will have effects on the results of the simulation as shown with the sensitivity analysis, 
but  they  were  necessary  to  complete  the  current  investigation  into  the  release  rates  of 
etonogestrel from the Implanon birth control implant. 
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Design Recommendations  
As  the  goal  of  this  project  was  to  model  the  current  device’s  behavior,  we  did  not 
consider improvements to Implanon’s diffusion rates or methods. These release rates are set by 
doctors and pharmacologists to deliver the required amount of drug to prevent pregnancy and are 
not within the scope of this project. However, as engineers, we naturally see a need to improve 
the mechanical structure of Implanon. Due to the fairly fragile shape (a long, thin rod), Implanon 
is susceptible to becoming broken or damaged while in the body.  Additionally, the implant 
should always be able to be felt through the skin, and when it is no longer palpable due to 
migration of the device or fibrosis, it can be a cause for alarm, and the removal process can 
become increasingly complicated. A possible improvement for this would be to re-evaluate the 
geometry  of  the  device  to  a  more  sturdy  shape  that  can  handle  mechanical  stresses  better. 
Additionally,  use  of  a  more  flexible  polymer  to  compose  the  scaffold  of  the  device  could 
improve structural properties of the device.  
Implanon is not free of side effects, but the side effects associated with it are similar to 
those of other forms of hormonal birth control, such as oral contraceptive pills, implants, or 
Depo-Provera.  These  side  effects  include  irregular  periods,  weight  gain,  abdominal  pain, 
headaches, and acne, but they usually dissipate after the first few months of use in most women. 
Many women will no longer have periods while using Implanon, and few will have anxiety and 
depression. These side effects are not due to the Implanon device itself, however, but rather to 
the hormonal etonogestrel. Therefore, no design changes can mitigate these symptoms except the 
discovery of a new molecule that does not induce these effects in women. 
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Appendix A 
  Schematics and Mathematical Statement of Simulation 
 
 
Figure A – A1: Schematic of Implanon Implant only. 
 
  Equation: 
 
  Boundary Conditions: 
Insulation, at all outer boundaries, drug remains in the tissue and is removed through the blood 
vessels only 
Initial Conditions: 
Co = 68 mg = 1668.0851 mol/m
3 initial drug concentration in the implant core  
Input Parameters: 
Table A – A1: Parameters Used in the Simulation 
Property  Values Used  Units  Source 
Core Diffusivity  1.84x10
-13  m
2/s  (van Laarhoven et al, 2002) 
Membrane Diffusivity  9.2x10
-15  m
2/s  (Implanon, 2009) 
Epidermis Diffusivity  1.0x10
-14  m
2/s  (Ebert, 1992) 
Dermis Diffusivity  5.8x10
-11  m
2/s  (Datta et al, 2010) 
Inward Flux  -7.5x10
-10 x c  mol/ m
2s  (Pereira et al, 1987) 
Purple region is the Implanon drug 
core, and the red region is the 
Implanon membrane. 
diameter = 0.002 m  18 
 
 
Table A – A2: Conversion of Parameters from Literature to Parameters Used in Simulation 
Property  Values  from 
Source 
Units 
Math Applied 
Values Used  Units 
Core Diffusivity  1.84x10
-9 cm
2/s  x (1 m
2 / 10000 cm
2)  1.84x10
-13  m
3/s 
Membrane 
Diffusivity 
9.2x10
-11 cm
2/s  x (1 m
2 / 10000 cm
2)  9.2x10
-15  m
3/s 
Epidermis 
Diffusivity 
1.0x10
-10 cm
2/s  x (1 m
2 / 10000 cm
2)  1.0x10
-14  m
3/s 
Dermis 
Diffusivity 
5.8x10
-7 cm
2/s  x (1 m
2 / 10000 cm
2)  5.8x10
-11  m
3/s 
Inward Flux  -1.8x10
-5  x  c 
mol/ cm
 min 
x (1/0.04 m) x (1 min/ 60 sec) x 
(1 m
2 / 10000 cm
2) 
-7.5x10
-10 x c  mol/ m
2s 
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Appendix B 
  Mesh Convergence 
 
Figure A – B1: Image of Mesh after Convergence, used in the Problem Solution. 
The mesh for this problem was created using the values for the mesh obtained from our 
mesh convergence.  The free mapped mesh element size for the two skin layers, and the core had 
a maximum element size undefined, as COMSOL provided the best mesh size.  
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Figure A – B2: Mesh Convergence Determination, found in the Implant Membrane 
Since there are different subdomains in our schematic, we decided to manually mesh 
converge in each subdomain separately.  We compared element size to the concentrations at a 
single point within that specific subdomain.  The subdomains pertaining to the skin layers and 
the core seemed to have a mesh convergence that always converged.  Therefore it seemed that 
our solution is independent of the mesh in the two skin layers and core.  However the membrane 
subdomain converged with an element size of 10000.  Therefore our mesh has an element size of 
10,000. 
 
   21 
 
Appendix C 
  Additional Information 
Table A – B1: Minimum and Maximum Concentrations of Etonogestrel in the Simulation. 
Time of Surface Plot   Minimum 
Concentration (mol/m
3) 
Maximum 
Concentration (mol/m
3) 
Maximum Core 
Concentration (mol/m
3) 
Initial (0 s)  0  1668.085  1668.085 
6 weeks (3628800 s)  0  997.487  975.970 
1 year (31536000 s)  6.016  236.172  115.820 
2 years (63072000 s)  5.211  90.122  33.570 
3 years (94608000 s)  2.182  45.462  13.780 
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